FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA Stock

FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA Share Price

DE000MG1XQ33

Real-time Bid/Ask 02:50:40 07/06/2024 pm IST
6.25 ^EUR / 6.37 ^EUR	+2.10%

Current month	-14.88%
1 month	-32.24%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ZEALAND PHARMA A/S

Chart FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA

Latest news about ZEALAND PHARMA A/S

Zealand Pharma A/S : announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	02:14pm	PU
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	02:09pm	GL
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL	06/06	GL
Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL	06/06	CI

More news

Quotes 5-day view

Date	Price	Change
07/24/07	6.06	-1.94%
06/24/06	6.18	-22.75%
05/24/05	8	-3.85%
04/24/04	8.32	+20.41%
03/24/03	6.91	-4.82%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 12:03 pm IST

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	ZEALAND PHARMA A/S
Issuer	Morgan Stanley
WKN	MG1XQ3
ISIN	DE000MG1XQ33
Date issued	09/04/2024
Strike	813.7 kr
Maturity	Unlimited
Parity	3.4 : 1
Emission price	10 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	15.17 €
Lowest since issue	5.75 €
Spread	0.12 €
Spread %	1.94%

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

More about the company

Ratings for Zealand Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Zealand Pharma A/S

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

651 DKK

Average target price

785.6 DKK

Spread / Average Target

+20.67%

Consensus